focus -WSS

focus

author：explore 2025-10-01 14:15:02 - browse：35

Today, if you want to know what scary family health secrets lay buried in your DNA or get screened for a lurking cancer, you have a lot of options. Laboratories have developed more than 75,000 genetic tests, with about 10 new ones entering the market daily. By the end of 2019, more than 26 million Americans had had their DNA decoded to some degree or another. Since then, that number has surely grown.

But this testing frenzy would have been inconceivable just 10 years ago. In part, that’s because the technology back then was so expensive. More importantly, until 2013, it was common practice for gene-hunting academics and companies to lock up their discoveries with DNA patents, effectively carving up the human genome into mini-monopolies. That year, the U.S. Supreme Court threw a bomb into the biotech world when it took up a landmark case that pitted cancer survivors and the American Civil Liberties Union against a diagnostics company called Myriad Genetics, which had obtained exclusive patents on the cancer-causing BRCA genes and made billions of dollars selling tests for them.

A new book called “The Genome Defense,” written by University of Utah science and technology law expert Jorge Contreras and being published Oct. 26, provides a front-row seat to the courtroom drama that would upend three decades of federal intellectual property law and chart a new course toward balancing corporate profits with the rights of all people to the information written into their DNA.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Why a market frenzy over new weight loss drugs defies logic

knowledge

WSS

Brain MRIs reveal impact of 'toxic stress' on Black children

STAT Readout Newsletter: Biotech news today

Warren pushes Witty on UnitedHealth's control over physicians

STAT Summit: Ending the crisis of Black deaths in the U.S.

PBM executives asked to testify by House panel

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Cancer drug shortages should be causing more outrage

The problems with dementia villages

Guidelines to prevent youth baseball injuries need more muscle

Lawmakers grill UnitedHealth CEO on Change cyberattack

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Jerome Adams on the need for new antivirals for Covid

Smaller biotechs seek to piggyback on weight loss drug boom

Anesthesiologist group: stop taking Ozempic before surgery

Study on Amgen’s bispecific immunotherapy produces positive data

hotspot

Class action alleges UnitedHealth concealed DOJ probe

GSK’s asthma push continues as drug succeeds in Phase 3 trials

BIO to announce reorganization, senior leaders expected to depart

Black vets could get higher VA benefits if race not used in lung test

STAT Summit: Meghan O’Rourke on making chronic illness visible

Is there really a nursing shortage in the U.S.?

hotspot

hotspot

knowledge

explore